DISCO’s pioneering surfaceome mapping platform transforms the current approach of target discovery for large molecule R&D. The technology identifies proteins and protein communities across the entire cancer cell surface in a scalable manner, thus addressing the need for target candidates for both mono- and bi-specific antibodies. These insights enable the development of a multitude of cancer-selective therapies, with the potential to boost efficacy and reducing side effects for patients. 

Biotechnology

Health Care

Life Sciences

Medical Devices

Therapeutics

DISCO Pharmaceuticals GmbH

DISCO Pharmaceuticals GmbH's headquarters in Cologne, Germany

Description

People (2)

Roman Thomas

Heike Angele

Jobs